| Literature DB >> 26425820 |
Fujimi Kudo1, Masashi Ikutani2, Yoichi Seki1, Takeshi Otsubo3, Yuki I Kawamura3, Taeko Dohi3, Kenshiro Oshima4, Masahira Hattori4,5, Susumu Nakae6,7, Kiyoshi Takatsu3,8, Satoshi Takaki1.
Abstract
Group 2 innate lymphoid cells (ILC2s) produce a significant amount of interleukin-5 (IL-5), which supports eosinophil responses in various tissues; they also produce IL-13, which induces mucus production and contributes to tissue repair or fibrosis. The ILC2s are activated by alarmins, such as IL-33 released from epithelia, macrophages and natural killer T (NKT) cells in response to infection and allergen exposure, leading to epithelial injury. We examined gene expression in lung ILC2s and found that ILC2s expressed Ifngr1, the receptor for interferon-γ (IFN-γ). Interferon-γ severely inhibited IL-5 and IL-13 production by lung and kidney ILC2s. To evaluate the effects in vivo, we used α-galactosylceramide (α-GalCer) to induce NKT cells to produce IL-33 and IFN-γ. Intraperitoneal injection of α-GalCer in mice induced NKT cell activation resulting in IL-5 and IL-13 production by ILC2s. Administration of anti-IFN-γ together with α-GalCer significantly enhanced the production of IL-5 and IL-13 by ILC2s in lung and kidney. Conversely, cytokine production from ILC2s was markedly suppressed after injection of exogenous IL-33 in Il33(-/-) mice pre-treated with α-GalCer. Hence, IFN-γ induced or already present in tissues can impact downstream pleiotropic functions mediated by ILC2s, such as inflammation and tissue repair.Entities:
Keywords: T helper type 2 cytokines; group 2 innate lymphoid cells; interferon-γ; interleukin-13; interleukin-5
Mesh:
Substances:
Year: 2015 PMID: 26425820 PMCID: PMC4693881 DOI: 10.1111/imm.12537
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397